4.7 Article

DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer

期刊

ONCOLOGIST
卷 16, 期 1, 页码 61-70

出版社

ALPHAMED PRESS
DOI: 10.1634/theoncologist.2010-0127

关键词

DNA mismatch repair; Pancreatic cancer; Single-nucleotide polymorphism; Survival

类别

资金

  1. National Institutes of Health (NIH) [CA098380]
  2. SPORE [CA101936]
  3. NIH Cancer Center [CA16672]
  4. Lockton Research Funds
  5. NATIONAL CANCER INSTITUTE [P20CA101936, R01CA098380, P30CA016672] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Purpose. DNA mismatch repair (MMR) maintains genomic stability and mediates cellular response to DNA damage. We aim to demonstrate whether MMR genetic variants affect overall survival (OS) in pancreatic cancer. Materials and Methods. Using the Sequenom method in genomic DNA, we retrospectively genotyped 102 single-nucleotide polymorphisms (SNPs) of 13 MMR genes from 706 patients with pancreatic adenocarcinoma seen at The University of Texas MD Anderson Cancer Center. Association between genotype and OS was evaluated using multivariable Cox proportional hazard regression models. Results. At a false discovery rate of 1% (p <=. 0015), 15 SNPs of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, TP73, and TREX1 in patients with localized disease (n = 333) and 6 SNPs of MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease (n = 373) were significantly associated with OS. In multivariable Cox proportional hazard regression models, SNPs of EXO1, MSH2, MSH3, PMS2L3, and TP73 in patients with localized disease, MSH2, MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease, and EXO1, MGMT, MSH2, MSH3, MSH6, PMS2L3, and TP73 in all patients remained significant predictors for OS (p <=. 0015) after adjusting for all clinical predictors and all SNPs with p <= .0015 in single-locus analysis. Sixteen haplotypes of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, RECQL, TP73, and TREX1 significantly correlated with OS in all patients (p <= .001). Conclusion. MMR gene variants may have potential value as prognostic markers for OS in pancreatic cancer patients. The Oncologist 2011; 16: 61-70

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据